Prevalence
The prevalence of PAH in the general population in Europe is approximately 1 in 20,000.
Clinical manifestations
The symptoms of PAH are non-specific and include breathlessness, fatigue, weakness, angina, syncope and abdominal distension. Symptoms at rest are reported only in very advanced cases. The physical signs of PAH include left parasternal lift , an accentuated pulmonary component of second heart sound, a pansystolic murmur of tricuspid regurgitation, a diastolic murmur of pulmonary insuffi ciency and a right ventricular third heart sound. Jugular vein distension, hepatomegaly, peripheral 
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Updated clinical classifi cation of pulmonary hypertension 1. Pulmonary arterial hypertension (PAH) 1´: Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis 2. Pulmonary hypertension due to left heart disease 3. Pulmonary hypertension due to lung diseases and/or hypoxaemia 4. Chronic thromboembolic pulmonary hypertension 5. PH with unclear and/or multifactorial mechanisms oedema, ascites and cool extremities characterise patients in a more advanced state. Lung sounds are usually normal. The examination may also provide clues as to the cause of PH. Telangiectasia, digital ulceration and sclerodactly are seen in scleroderma, while inspiratory crackles may point towards interstitial lung disease. The stigmata of liver disease such as spider naevi, testicular atrophy and palmar erythema should be looked for. If digital clubbing is encountered, an alternative diagnosis such as congenital heart disease or pulmonary venoocclusive disease should be sought.
Diagnosis
The evaluation process of a patient with suspected PH requires a series of investigations intended to confi rm the diagnosis, clarify the clinical group of PH, the specifi c aetiology within the PAH group, and evaluate the functional and haemodynamic impairment. The various investigative tests can be combined in a diagnostic algorithm (fi gure 1) which, for practical purposes, can be divided into four phases:
Suspicion
Clinical suspicion of PH should be aroused when there are symptoms such as breathlessness without overt signs of specifi c heart or lung disease, in cases of screening in predisposing conditions or in cases of incidental fi ndings.
Detection
The detection of PH requires investigations able to confi rm the diagnosis, e.g. clinical examination, ECG, chest radiograph and transthoracic echocardiography.
Group identifi cation
The next step is the identifi cation of the clinical group. This is accomplished by the use of essential investigations such as pulmonary function tests, arterial blood gases and ventilation-perfusion lung scans. In particular circumstances, additional tests can be performed such as high-resolution computed tomography (CT) of the chest, contrast-enhanced spiral CT of the lung and pulmonary angiography.
Evaluation
After the diagnosis of PAH (clinical group 1), additional investigations are required for the exact identifi cation of the type and for the assessment of exercise capacity and haemodynamics.
Referral
The purpose of a referral centre is to undertake assessment and investigation of all causes of PH, routinely manage appropriate patients with PAH including the provision of specific drug therapy, work with other healthcare providers to obtain best outcomes for patients, and undertake audit, research and education. Since, in general, centres with a high volume of patients tend to obtain best outcomes, referral centres will need to have suffi cient patients on chronic therapy and new referrals to warrant this status.
Treatment and follow-up
The therapy of PAH patients cannot be considered as a mere prescription of drugs, but is characterised by a complex strategy which includes the evaluation of severity, supportive and general measures, the assessment of vasoreactivity, the estimation of [3] with permission from the publisher. therapy need to be initiated aft er PAH diagnosis. Acute vasoreactivity testing should be performed and high-dose calcium channel blockers therapy performed as appropriate. Non-responders to acute vasoreactivity testing who are in World Health Organization (WHO)/ New York Heart Association (NYHA) functional class II should be treated with an endothelin receptor antagonist, a PDE-5 inhibitor or a guanylate cyclase stimulator. Non-responders to acute vasoreactivity testing, or responders who remain in (or progress to) WHO/NYHA functional class III should be considered candidates for treatment with an endothelin receptor antagonist, a PDE-5 inhibitor, a prostanoid or a guanylate cyclase stimulator.
As head-to-head comparisons among diff erent compounds are not available, no evidence-based fi rst-line treatments can be proposed. In this case, the choice of the drug is dependent on a variety of factors, including the approval status, the route of administration, the side-eff ect profi le, patient preferences, costs and physician's experience. Some authors still use fi rst-line i.v. epoprostenol in WHO/NYHA functional class III patients, due to its demonstrated survival benefi ts. Continuous i.v. epoprostenol may be considered as fi rst-line therapy for WHO/NYHA functional class IV PAH patients because of the demonstrated survival benefi t in this subset. Subcutaneous and i.v. treprostinil has also been approved for the treatment of WHO/ NYHA functional class IV patients. Both endothelin receptor antagonists and PDE-5 inhibitors are considered as a second line for severely ill patients, in WHO/NYHA functional class IV patients initial combination therapy may also be considered. In case of inadequate clinical response to fi rst-line therapy, sequential combination therapy can be considered. Combination therapy can either include a prostanoid plus an endothelin receptor antagonist or an endothelin receptor antagonist plus a PDE-5 inhibitor or a prostanoid plus a PDE-5 inhibitor. Guanylate cyclase stimulators may be utilised instead of a PDE-5 inhibitor. The combination of these two compounds is contraindicated. Balloon atrial septostomy and/or lung transplantation are indicated for PAH with inadequate clinical response despite optimal medical therapy or where medical treatments are unavailable.
This factsheet adapted from [1] .
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